Schrödinger, Inc.
Financials
Valuation Metrics
Schrödinger, Inc.'s Market Cap is $2.17B. At end of 2025 it was $1.31B. Ranked #1937 of 3,121 in US market (top 62%), #729 of 1,463 on NASDAQ (top 50%), #115 of 205 in Health Care Equipment & Services (top 56%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $2.17B | US#1,937/3,121 Sec#115/205 |
| Revenue | $259M | US#2,510/3,121 Sec#162/205 |
| Net Income | $-54M | US—/3,121 Sec—/205 |
| Total Assets | $640M | US#2,677/3,121 Sec#150/205 |
| Net Assets | $329M | US#2,483/3,121 Sec#140/205 |
| Employees | 850 | US#2,061/3,121 Sec#143/205 |
| Value | ||
| P/B | 6.59x | US#2,436/3,121 Sec#152/205 |
| P/S | 8.37x | US#2,642/3,121 Sec#178/205 |
| FCF Yield | -1.50% | US—/3,121 Sec—/205 |
| Profitability | ||
| ROE | -16.52% | US#2,454/3,121 Sec#146/205 |
| ROA | -8.48% | US#2,625/3,121 Sec#153/205 |
| Op. Margin | -59.24% | US#2,692/3,121 Sec#183/205 |
| Revenue Growth | 8.88% | US#1,376/3,121 Sec#92/205 |
| Financial Health | ||
| Debt Ratio | 94.67% | US#1,050/3,121 Sec#99/205 |
| Total Debt | $108M | US#2,427/3,121 Sec#137/205 |
| FCF | $-32M | US#2,478/3,121 Sec#172/205 |
| Cash | $288M | US#1,455/3,121 Sec#84/205 |
| Current Ratio | 2.71x | US#898/3,121 Sec#89/205 |
| Dividend | ||
| Div. Yield | 0.00% | US—/3,121 Sec—/205 |
| Payout Ratio | 0.00% | US—/3,121 Sec—/205 |
| Performance | ||
| 1Y Return | 47.68% | US#469/3,121 Sec#44/205 |
| 1M Return | 46.20% | US#7/3,121 Sec#1/205 |
| From 52W High | -4.57% | US#30/3,121 Sec#8/205 |
| 1Y MDD | -50.18% | US#2,472/3,121 Sec#148/205 |
| Trading | ||
| Volume | 4,932,541 shares | US#168/3,121 Sec#4/205 |
| Trading Value | $144M | US#375/3,121 Sec#28/205 |
| Per Share | ||
| EPS | $-0.73 | US—/3,121 Sec—/205 |
| BPS | $4.40 | US#2,327/3,121 Sec#146/205 |
Company Info
Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications in the United States, the Asia-Pacific, Europe, Middle East, Africa, and internationally. The company operates in two segments, Software and Drug Discovery. The Software segment sells its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. It has a research collaboration and license agreement with Novartis Pharma AG to advance multiple development candidates. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.